Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis

 Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents
                  and Xeljanz to Treat Rheumatoid Arthritis

The New Oral JAK Inhibitor Xeljanz Has Yet to Carve-Out a Distinct Place in
the RA Treatment Algorithm, According to a New Report from BioTrends Research
Group

PR Newswire

EXTON, Pa., Oct. 30, 2013

EXTON, Pa., Oct. 30, 2013 /PRNewswire/ --BioTrends Research Group, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that surveyed U.S. rheumatologists are moderately satisfied with
the currently available biologic agents as well as Pfizer's Xeljanz for the
treatment of rheumatoid arthritis (RA). Physicians have a strong preference
for the more established, market-leading TNF-alpha inhibitors, Amgen/Pfizer's
Enbrel and AbbVie's Humira, over other biologic agents and Xeljanz. Surveyed
physicians rated Enbrel and Humira highest in product satisfaction, perceive
these agents as having the most favorable benefit/risk profiles, and they
indicate that both products outperform other TNF-alpha inhibitors on the most
important stated attributes to prescribing RA therapies. Consequently, these
two biologic therapies are used typically as first- or second-line biologic
treatment after conventional disease-modifying antirheumatic drug (DMARD)
therapy failure.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends^®:Rheumatoid Arthritis (US)  report finds that
rheumatologists participating in this study also rated Xeljanz, the newest
entrant in the RA market, moderately. However, Xeljanz was rated significantly
lower than all biologics on overall product performance. In addition, Xeljanz
has yet to carve out a distinct place in the RA treatment algorithm.
Physicians reported using the product most often after one to three TNF-alpha
inhibitor failures. The report also finds that only 14 percent of Xeljanz
patients were biologic naive.

"Xeljanz was on the market 9 months at the time this study was fielded, so
rheumatologists may not be certain as to which patient types would benefit
most from Xeljanz, which is why they are trying it on different patient types
at various points in the treatment algorithm," said BioTrends Senior Director
Greta Unger. "A relatively low percentage of Xeljanz patients were biologic
naive even though it has been approved for use in this patient group. It will
be interesting to see if physicians' behavior changes over time as they gain
more experience with the product."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please visit www.bio-trends.com. BioTrends is a
Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com
 
Press spacebar to pause and continue. Press esc to stop.